Prognostic grouping of metastatic prostate cancer using conventional pretreatment prognostic factors
暂无分享,去创建一个
[1] P. Klarskov,et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5 , 2008, Scandinavian journal of urology and nephrology.
[2] M. Ruutu,et al. Ten‐year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy , 2007, The Prostate.
[3] Masatoshi Watanabe,et al. CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer. , 2005, European urology.
[4] I. Thompson,et al. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. , 2003, The Journal of urology.
[5] T. D. de Reijke,et al. Prognostic factor analysis in patients with advanced prostate cancer treated by castration plus anandron or placebo: a final update. , 2002, European urology.
[6] T. Tammela,et al. PSA Decline Is an Independent Prognostic Marker in Hormonally Treated Prostate Cancer , 1999, European Urology.
[7] J. Aro,et al. Pretreatment plasma testosterone and estradiol levels in patients with locally advanced or metastasized prostatic cancer , 1999, The Prostate.
[8] M. Ruutu,et al. Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group. , 1998, British journal of urology.
[9] R. Sylvester,et al. The Importance of Prognostic Factors in the Interpretation of Two EORTC Metastatic Prostate Cancer Trials , 1998, European Urology.
[10] P. Ruff,et al. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. , 1997, American journal of clinical oncology.
[11] H. Danielsen,et al. Prognostic factors in patients with metastatic (stage D2) prostate cancer: experience from the Scandinavian Prostatic Cancer Group Study-2. , 1997, The Journal of urology.
[12] H. Grönberg,et al. Prostate cancer mortality in northern Sweden, with special reference to tumor grade and patient age. , 1997, Urology.
[13] C. Abbou,et al. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate. , 1997, The Journal of urology.
[14] A. Tewari,et al. The proportional decrease in prostate specific antigen level best predicts the duration of survival after hormonal therapy in patients with metastatic carcinoma of the prostate. , 1996, British journal of urology.
[15] T. Peters,et al. Prostate-specific antigen and prognosis in patients with metastatic prostate cancer--a multivariable analysis of prostate cancer mortality. , 1995, British journal of urology.
[16] L. Holmberg,et al. Erythrocyte sedimentation rate as a tumor marker in human prostatic cancer. An analysis of prognostic factors in 300 population‐based consecutive cases , 1992, Cancer.
[17] H. Yamanaka,et al. Significance of a new stratification of alkaline phosphatase and extent of disease in patients with prostate carcinoma with bone metastasis , 1992, Cancer.
[18] L. Holmberg,et al. Prognostic factors in progression-free survival and corrected survival in patients with advanced prostatic cancer: results from a randomized study comprising 150 patients treated with orchiectomy or estrogens. , 1991, The Journal of urology.
[19] M. Terris,et al. Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] G. Chodak,et al. Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer. , 1991, Urology.
[21] N. Vogelzang,et al. Independent Prognostic Factors in Patients With Metastatic (Stage D2) Prostate Cancer , 1991 .
[22] N. Vogelzang,et al. INDEPENDENT PROGNOSTIC FACTORS IN PATIENTS WITH METASTATIC (STAGBE D2) PROSTATE CANCER , 1991 .
[23] H. Yamanaka,et al. The Significance of Erythrocyte Sedimentation Rate as a Prognostic Factor for Patients with Prostate Cancer: Gunma Urological Oncology Study Group Investigation , 1990, Japanese journal of cancer research : Gann.
[24] H. Zincke,et al. Prostate-specific antigen testing in untreated and treated prostatic adenocarcinoma. , 1990, Mayo Clinic proceedings.
[25] F. Debruyne,et al. Analysis of prognostic factors in disseminated prostatic cancer. An update , 1990 .
[26] P. Mulders,et al. Analysis of prognostic factors in disseminated prostatic cancer. An update. Dutch Southeastern Urological Cooperative Group. , 1990, Cancer.
[27] S. Ishikawa,et al. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. , 1989, The Journal of urology.
[28] M. Soloway,et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan , 1988, Cancer.
[29] J. Hardy,et al. Bone imaging and serum phosphatases in prostatic carcinoma. , 1985, British journal of urology.
[30] H. Adlercreutz,et al. Hormonal pattern in prostatic cancer. I. Correlation with local extent of tumour, presence of metastases and grade of differentiation. , 1981, Acta endocrinologica.
[31] W. Ashburn,et al. Nuclear bone imaging in metastatic cancer of the prostate , 1981, Cancer.
[32] L. Theodorsen,et al. Experiences with the Scandinavian recommended methods for determinations of enzymes in blood. A report by the Scandinavian Committee on Enzymes (SCE) , 1981, Scandinavian journal of clinical and laboratory investigation.
[33] K. Kuoppasalmi. Plasma testosterone and sex-hormone-binding globulin capacity in physical exercise. , 1980, Scandinavian journal of clinical and laboratory investigation.
[34] D L Doxey,et al. PRACTICAL HAEMATOLOGY , 1939, The Veterinary record.